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Introduction
Multiple sclerosis (MS) is a demyelinating inflamma-
tory disease of the central nervous system (CNS), 
which causes walking impairment in up to 70% of 
subjects with this diagnosis1 and may occur already 
early in the disease process.2 Walking impairment 
treatment has been approached mainly by rehabilita-
tion and exercise therapies, showing some degree of 
improvement.3
Symptomatic treatment with fampridine has demon-
strated walking improvement in MS patients.4–8 
Fampridine (4-aminopyridine), a wide-spectrum 
potassium channel blocker,9 prevents the release of 
potassium from potassium channels exposed due to 
the inflammatory demyelinating process in the CNS; 
consequently, disrupted action potential conduction 
may be partly restored, yielding improvements in 
ambulation.10
Currently, most data available on fampridine efficacy 
in MS patients are limited to information from pla-
cebo-controlled, randomized clinical trials in artificial 
clinical study environments,5–7 which demonstrated 
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Objective: The primary objective of this real-world study was to describe the response to fampridine and 
changes of gait parameters in multiple sclerosis (MS) patients’ walking disability (Expanded Disability 
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Walking Scale (MSWS-12), the GAITRite electronic walkway system, and the patients’ clinical global 
impression (CGI). Multimodal gait assessment was compared with the clinician’s impression of overall 
improvement after 2 weeks.
Results: In total, 189 subjects were included, of which 133 (70.37%) were responders to fampridine (RF), 
according to physician’s judgement. Looking at independent multimodal gait assessment, RFs showed 
improvement of 12.60% in the T25FW, 19.25% in the 2-MWT, 21.12% in the MSWS-12, and 6.54% 
in their Functional Ambulation Profile (FAP) score. The combination of the T25FW and the MSWS-12 
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that roughly 35% to 42% of subjects are responders to 
fampridine (RF). However, in clinical practice, the 
clinician is responsible to take the decision of fampri-
dine response according to EMA’s recommendations, 
which states that fampridine must be discontinued in 
subjects not showing any improvement after 2 weeks 
of treatment.11
Studies in a real-world setting have been made, most 
of them applying Hobart’s criteria of clinical signifi-
cant improvement,12–14 which consider an improve-
ment ⩾20% in the timed 25-foot walk test (T25FW) 
as significant, thus yielding similar results to the trials 
performed by Goodman et al., and raising the ques-
tion of a possible larger benefit in a real-world setting 
by applying more permissive RF criteria, modeled 
after EMA’s recommendation, and possible improve-
ment in other functions besides walking speed meas-
ured with the T25FW. Other trials documented 
different responder rates: In a small multicenter study, 
Fragoso et al.15 reported a 70% RF rate using the 
T25FW, similar to another trial applying less strict 
criteria for defining RF, resulting in similar propor-
tion of RF.16
No real-world study investigating patients in clinical 
practice has assessed response to fampridine using 
EMA’s recommendations and physician’s global judge-
ment to characterize the response to fampridine treat-
ment over time. This information is needed to offer a 
real-world-oriented solution for clinical decisions.
The primary objective of this study was to describe 
clinical response and changes in gait parameters in 
subjects with MS and walking disability using a mul-
timodal walking assessment in a real-world setting, 
after being treated with fampridine, with response cri-
teria based on EMA’s recommendations.
Methods
We conducted an open-label, monocentric real-world 
study investigating the effect of fampridine treatment 
on patients with MS applying a comprehensive multi-
modal walking assessment at the MS Center Dresden, 
Germany. First results about the methodological 
aspects of the assessment were published previously.17 
The study was approved by the ethical committee of 
the University Clinic of Dresden, Germany. All par-
ticipants provided written informed consent.
A total of 211 adult MS patients were recruited before 
starting treatment with fampridine between 2011 and 
2014. Patients were eligible to participate in the study 
in case of a confirmed MS diagnosis, indication for 
fampridine treatment, and the ability to walk continu-
ously for at least 2 minutes according to self-report. 
Patients were excluded if they had a contraindication 
for initiating treatment with fampridine, or had severe 
walking disability impairing performance of the 
walking tests. Patients were tested prior to the admin-
istration of a dose of 10 mg of Fampyra® (Biogen, 
Cambridge, MA, USA) twice daily (baseline), as well 
as 2 weeks following the initial test (time point 2).
As in everyday practice, treating neurologists 
classified the subjects as RF and non-responders to 
fampridine (NRF). Neurologists generated an overall 
assessment regarding walking performance after 
2 weeks, leading to the decision whether to continue or 
stop fampridine treatment, based on EMA’s European 
Public Assessment Reports (EPAR) on fampridine,11 
described above.
We divided our population according to their disabil-
ity as recorded with the Expanded Disability Status 
Scale (EDSS),18 as subjects with mild walking disa-
bility (EDSS ⩽ 4.5), moderate walking disability 
(EDSS = 5.0– 6.0), and severe walking disability 
(EDSS ⩾ 6.5); subjects were also divided according 
to their diagnosis as relapsing-remitting MS (RRMS), 
secondary progressive MS (SPMS), and primary pro-
gressive MS (PPMS). Patients were further grouped 
according to either improvement or non-improvement 
according to their clinical global impression (CGI), a 
score based on the patient’s impression of self-
improvement,19 after 2 weeks.
Multimodal walking assessment consisted of the fol-
lowing tests:
Walking speed. The T25FW is a component of the 
Multiple Sclerosis Functional Composite (MSFC) 
and has shown reliability of walking speed testing 
in people with MS.20,21 Testing was performed 
according to the instructions provided by the 
MSFC,20 for which the mean value in seconds of 
two attempts was used for analysis.
Qualitative analysis of gait: The computerized 
GAITRite (CIR Systems, Inc., Havertown, PA, 
USA) system is an instrumented walkway which 
enables quantitative assessment of spatiotemporal 
parameters of gait. The main outcome, the Functional 
Ambulation Profile (FAP), has been validated as key 
marker of gait impairment in MS patients.22
Walking endurance test. The 2-minute walking 
test (2-MWT) has shown good reliability and 
validity in testing walking endurance in patients 
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with MS.23 To implement endurance testing in 
clinical practice, we decided to use the 2-minute 
instead of the 6-minute duration as the 2-MWT 
has demonstrated good correlation with longer 
endurance tests24
Self-walking evaluation by the patient. The impact 
of MS on the participants’ perceived walking ability 
was assessed using the 12-item Multiple Sclerosis 
Walking Scale (MSWS-12) questionnaire25 using a 
score from 0 to 100. As secondary outcome meas-
ures, we included the patients’ CGI,19 subjects with 
a CGI outcome from 5, slight improvement, or bet-
ter, up to 7, were considered as having a positive 
CGI score.
For the collection and management of data, the 
Multiple Sclerosis Documentation System (MSDS3D) 
was used.26 All statistical analyses were performed 
using the IBM SPSS Software for Windows (Version 
23.0; IBM Corporation, Armonk, NY, USA). The sig-
nificance level for all statistical tests was set at 
p < 0.05. If not stated otherwise, arithmetic mean val-
ues and standard deviations (SD) were reported. 
Analyses of variance (ANOVAs) and t-tests for paired 
samples for normally distributed outcomes, as well as 
Kruskal–Wallis H tests and Wilcoxon’s signed rank 
test for not normally distributed outcomes, were per-
formed to test for multiple group differences and for 
score differences of the four walking tests between 
the first and the second time point, respectively. 
Comparisons between two groups were done using 
t-tests for independent samples and Mann–Whitney 
U-tests, respectively. Receiver operating characteris-
tic (ROC) curves were computed to determine the 
sensitivity and specificity of each test in relation to 
neurologists’ clinical judgement. The area under the 
curve (AUC) and Youden’s J statistic were calculated 
to estimate the overall potential and the specific cut-
off values for each test. We used Kendall’s tau-b for 
correlational analyses between study outcomes and 
Fleiss’ kappa for assessing the agreement between 
neurologists and patients on the dichotomized overall 
improvement of patients’ walking abilities.
Results
A total of 211 subjects were screened, and 189 were 
included in the study. Twenty subjects were excluded 
due to non-compliance with appointments or medica-
tion or physical inability to perform the tests; one sub-
ject had a diagnosis other than definite clinical MS 
and another had a significant adverse effect after 
baseline examination (see below). Compliance with 
medication was 98.9% in included subjects during 
observation. Subjects in the mild disability group 
were younger than those in the other disability groups 
(p = 0.035 and p = 0.003, moderate and severe disabil-
ity in the age subgroup, respectively,) and those with 
mild disability had a significantly shorter disease 
course than those with severe disability (p = 0.028). 
Subjects with RRMS were also younger (47.07 ± 9.40 
vs 57.11 ± 9.62), had a significantly lower EDSS 
(4.63 ± 1.28 vs 5.70 ± 1.06) than those with other diag-
noses (p < 0.001), and had a significantly shorter dis-
ease course than those with SPMS (11.22 ± 6.85 vs 
15.38 ± 12.43; p = 0.011). All other characteristics 
were comparable among groups (see Table 1).
Adverse effects are listed in Table 2, of which nausea 
was the most common (N = 5, 2.65%). One subject 
had an epileptic seizure during observation; medica-
tion was suspended and subject failed to attend fur-
ther appointments.
A total of 153 subjects (80.95%) showed improve-
ment of 10% or greater in at least one test or more, out 
of the four possible, after 2 weeks, while 36 subjects 
(19.05%) failed to show minimal improvement of 
10% in any test (see Figure 1).
The 2-MWT and the MSWS-12 had the largest pro-
portion of subjects showing at least minimal improve-
ment of 10% (N = 113, 59.79% and N = 110, 58.51%, 
2-MWT and MSWS-12, respectively; see Figure 1).
There was a mean general positive and significant 
improvement in all subjects in all four walking tests 
(p < 0.001; see Table 3). The greatest improvement 
was noted in their self-perceived walking abilities 
(MSWS-12: 15.21%, p < 0.001). According to CGI 
scores, 117 subjects (61.9%) had subjective improve-
ment: 79 subjects (41.8%) had a slight improvement, 
34 (17.99%) were much improved, and 4 (2.12%) 
were very much improved after 2 weeks.
Our sample was divided according to their response 
to fampridine in 133 responders (70.37%) and 56 
non-responders (29.63%), following physician’s 
overall judgement of improvement.
RFs showed an average improvement of 12.60% 
(T25FW) in their speed, 19.25% in their mean distance 
(2-MWT), 21.12% in their self-perceived walking per-
formance (MSWS-12), and 6.54% in their FAP score.
In contrast, NRFs did not show any significant 
improvement in any of the walking tests (see Table 3). 
RFs also scored a better mean CGI score than NRFs 
after the time frame of 2 weeks (median = 5, interquar-
tile range (IQR) = 1 vs median = 4, IQR = 1, respond-
ers and non-responders, respectively; p < 0.001).
Multiple Sclerosis Journal 24(10)
1340 journals.sagepub.com/home/msj
As mentioned above, 117 subjects (61.9%) had sub-
jective improvement according to their CGI. Subjects 
with a positive CGI score performed significantly 
better at 2 weeks in comparison with their baseline 
measurement in all four walking tests (p < 0.001, see 
Table 4). This group of subjects showed a 16.16% 
Table 1. Sample characteristics.
All patients Mild disability Moderate 
disability
Severe 
disability
Responders to 
fampridine
Non-responders 
to fampridine
 N = 189 N = 68 N = 70 N = 51 N = 133 N = 56
Age Mean ± SD 53.55 ± 10.83 49.13 ± 1.37 54.08 ± 10.35 56–86 ± 10.19 53.89 ± 11.42 52.75 ± 9.32
Range 25–75 25–71 29–74 25–71 25–74 33–75
Gender
 Female 122 (64.55%) 40 (58.82%) 45 (64.29%) 37 (72.45%) 89 (66.92%) 33 (58.93%)
 Male 67 (35.45%) 28 (41.18%) 25 (35.71%) 14 (27.55%) 44 (33.08%) 23 (47.07%)
Diagnosisa
 RRMS 77 (40.74%) 42 (61.76%) 27 (38.57%) 8 (15.69%) 58 (43.61%) 19 (33.93%)
 SPMS 61 (32.28%) 15 (22.06%) 21 (30%) 25 (49.02%) 39 (29.32%) 22 (39.29%)
 PPMS 50 (26.46%) 10 (14.71%) 22 (31.43%) 18 (35.29%) 35 (26.32%) 15 (26.79%)
Treatment
 None 79 (41.8%) 16 (23.53%) 33 (47.14%) 30 (58.82%) 53 (39.85%) 26 (43.46%)
 Interferon 17 (8.99%) 8 (11.76%) 7 (10%) 2 (3.92%) 14 (6.77%) 3 (5.36%)
 Glatiramer 
acetate
28 (14.82%) 14 (20.59%) 10 (14.29%) 4 (7.84%) 19 (14.29%) 9 (16.07%)
 Natalizumab 17 (8.99%) 9 (13.24%) 5 (7.14%) 3 (5.88%) 15 (11.28%) 2 (3.57%)
 Fingolimod 21 (11.11%) 11 (16.18%) 7 (10%) 2 (3.92%) 12 (9.02%) 8 (14.29%)
 Mitoxantrone 5 (2.65%) 0 1 (1.43%) 4 (7.84%) 4 (3.01%) 1 (1.79%)
 Azathioprine 2 (1.06%) 1 (1.47%) 1 (1.43%) 0 1 (0.75%) 1 (1.79%)
 Studyb 20 (10.58%) 9 (13.24%) 6 (8.57%) 6 (11.76%) 15 (11.28%) 5 (8.93%)
EDSS Mean ± SD 5.22 ± 1.29 3.63 ± 0.63 5.73 ± 0.37 6.55 ± 0.15 5.15 ± 1.32 5.39 ± 1.19
Range 2.0–7.5 2.0–4.5 5.0–6.0 6.5–7.0 2.0–7.0 2.5–7.5
Disease 
duration
Mean ± SD 12.92 ± 10.83 10.42 ± 5.88 13.86 ± 8.73 14.61 ± 7.26 13.14 ± 8.21 12.35 ± 7.1
Range 1.0–39.0 1.0–27 1.0–39 3.0–35 1.0–39 1.0–28
MS: multiple sclerosis; SD: standard deviation; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; EDSS: 
Expanded Disability Status Scale.
aOne subject with MS diagnosis, but MS course unclear.
bSubjects were taking part in a randomized, double-blind study. Medication received unknown.
Table 2. Adverse effects.
Adverse effect N = 190
Nausea 5 (2.63%)
Vertigo 4 (2.11%)
Fatigue 2 (1.05%)
Headache 2 (1.05%)
Insomnia 2 (1.05%)
Epileptic seizure 1 (0.53%)
Anxiousness 1 (0.53%)
Diarrhea 1 (0.53%)
Tremor 1 (0.53%)
Paresthesia 1 (0.53%)
Total 20 (10.53%)
Figure 1. Proportion of subjects and percentage 
improvement shown in each walking test are represented 
in four different categories according to percentage of 
improvement from baseline to 2 weeks.
2-MWT: 2-minute walk test; FAP: Functional Ambulation Profile; 
MSWS-12: 12-item Multiple Sclerosis Walking Scale; T25FW: 
timed 25-foot walk test.
FA Rodriguez-Leal, R Haase et al.
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mean improvement in their T25FW, 20.67% in the 
2-MWT, 21.74% in the MSWS-12, and 5.49% in the 
FAP score. However, estimates of the CGI improve-
ment group were not significantly better than those of 
RF in any of the four walking tests during the 2-week 
period resulting from the high overlap between those 
two subgroups; 113 patients who showed a positive 
CGI score (96.58%) were also in the RF group.
Cut-off values for the classification into RFs and NRFs 
by neurologists’ global judgement were determined with 
ROC curves (Youden’s J). The T25FW (AUC = 0.804, 
p < 0.001) and the MSWS-12 (AUC = 0.801, p < 0.001) 
yielded the best overall sensitivity and specificity of a 
single test (see Table 5). In case of multiple tests, a com-
bination (sum of percental improvement) of T25FW and 
MSWS-12 (AUC = 0.858, p < 0.001, J = 18.20%) was in 
favor for indicating response to fampridine providing 
even better classification than a set of all four tests 
(AUC = 0.815, p < 0.001) or any other combination. For 
the analysis of patients’ self-perception, we used the 
dichotomized CGI (did improve/did not improve) with 
the ROC curves and found similar results: a combination 
(sum of percental improvement) of T25FW and MSWS-
12 was the most powerful test setting. In addition, there 
was a substantial agreement (Fleiss’ kappa = 0.61) 
between neurologists and patients about the individual 
improvement of patients’ walking abilities.
There was a significant correlation in three of 
four tests and the CGI, but not between the EDSS 
and the walking performance tests (see Table 6). 
Correspondingly, patients’ disability did not influ-
ence performance measured as relative improvement 
in any of the four walking tests or in the CGI. 
Furthermore, the type of diagnosis (RRMS, SPMS, 
or PPMS) did not have a significant effect on the 
response of subjects as measured in any of the four 
walking tests or the CGI.
Discussion
The main objective of this study was to describe 
fampridine response in MS patients in clinical 
practice assessed by physicians’ global judgement, 
and according to EMA’s recommendations on 
fampridine.
This real-world study adds new important informa-
tion to the current literature about the effects of fam-
pridine on walking function in clinical practice and 
contributes to build on the existing real-world experi-
ence with the use of this drug, describing the largest 
MS sample in that aspect to our knowledge. Our study 
provides evidence that physicians’ global judgement T
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Table 4. Patients with and without improvement of their CGI score.
CGI improvementa CGI non-improvement
 N = 117 N = 72
 Baseline 2 weeks Improvementb p-value Baseline 2 weeks Improvementb p-value
T25FWc 12.50 ± 10.93 10.48 ± 7.84 16.16% <0.001 12.78 ± 11.01 12.92 ± 12.72 –1.10% 0.162
2-MWTd 92.18 ± 47.20 111.23 ± 54.29 20.67% <0.001 90.69 ± 46.84 95.22 ± 48.52 5.00% 0.084
MSWS-12d 71.22 ± 16.90 55.74 ± 17.46 21.74% <0.001 74.73 ± 16.48 70.62 ± 18.75 5.50% 0.017
FAPc 74.07 ± 18.95 80.40 ± 19.00  8.55% <0.001 71.29 ± 20.36 73.87 ± 19.15 3.62% 0.035
CGI: clinical global impression; T25FW: timed 25-foot walk test; 2-MWT: 2-minute walking test; MSWS-12: 12-item Multiple Sclerosis Walking Scale; FAP: 
Functional Ambulation Profile.
aCGI Improvement or positive score was defined as a slight improvement or greater in the CGI score given by the patient at 2 weeks.
bConsists of mean score difference from baseline to 2 weeks, expressed as percentage.
cWilcoxon’s test for paired differences.
dt-test for paired differences.
Table 5. AUC and cut-off scores for gait metrics according to physicians’ judgement and patients’ CGI score.
Physicians’ judgement CGI
 AUC Cut-off AUC Cut-off
 Area 95% CI Score Percental 
improvementa
p-value Area 95% CI Score Percental 
improvementa
p-value
T25FWb 0.804 0.738–0.871 1.35 10.69% <0.001 0.716 0.639–0.793 0.71 5.65% <0.001
2-MWTc 0.706 0.622–0.790 8.299 9.06% <0.001 0.682 0.601–0.764 6.43 7.02% <0.001
MSWS-12d 0.801 0.733–0.869 11.42 15.77% <0.001 0.743 0.671–0.816 12.4 16.68% <0.001
FAPe 0.628 0.539–0.717 6.698 9.01% 0.01 0.564 0.474–0.654 1.67 2.24% 0.167
T25FW+ 
MSWS-12
0.858 0.803–0.914 NA 18.20% <0.001 0.76 0.690–0.831 NA 9.97% <0.001
CGI: clinical global impression; AUC: area under the curve; T25FW: timed 25-foot walk test; 2-MWT: 2-minute walking test; MSWS-12: 12-item Multiple 
Sclerosis Walking Scale; FAP: Functional Ambulation Profile.
aCalculated per Youden’s J.
bScore in seconds.
cScore in meters.
dPercentual score, according to the MSWS-12.
eScore from 0 to 100.
Table 6. Correlations between patients’s disability measured by EDSS and walking test score differences at two weeks.
Correlations
 EDSS CGI T25FW 2-MWT MSWS-12
CGI –0.026 1  
T25FWa 0.052 0.311b 1  
2-MWTa 0.007 0.230b 0.371b 1  
MSWS-12a 0.074 0.337b 0.230b 0.170b 1
FAPa 0.093 0.110 0.263b 0.165b 0.031
EDSS: Expanded Disability Status Scale; CGI: clinical global impression; T25FW: timed 25-foot walk test; 2-MWT: 2-minute walking test; MSWS-12: 12-item 
Multiple Sclerosis Walking Scale; FAP: Functional Ambulation Profile.
aA difference between baseline score and the score after 2 weeks is represented.
bCorrelation is significant at the 0.01 level (two-tailed).
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is a reliable outcome for determining response to fam-
pridine over time, as RF performed significantly bet-
ter in all multimodal gait parameters compared to 
those in our NRF subgroup.
Our sample consisted mostly of females with a diag-
nosis of RRMS, similar to current epidemiological 
reports.27 Most subjects did not receive a DMT, due 
to the majority of them having a progressive form of 
the disease.28 Age and EDSS differences in different 
disability and diagnosis groups, although significant, 
did not cause a significant effect in the response to 
fampridine.
Most subjects (80.95%) showed improvement in at 
least one of the tests included in the multimodal walk-
ing model and most of those individuals had improve-
ment in three of the four walking tests, being the 
2-MWT and the MSWS-12, the tests with the larger 
proportion of subjects showing at least 10% improve-
ment, and most had an improvement of ⩾30% in their 
scores at 2 weeks in the mentioned tests. In overall 
score improvement of all patients, all tests showed a 
significant improvement after 2 weeks, although the 
2-MWT and the MSWS-12 showed as well the largest 
percentage improvement (14.76% and 15.21% 
improvement in 2-MWT and MSWS-12, respec-
tively). This finding suggests that fampridine exerts its 
benefits in a variety of gait parameters besides speed; 
moreover, the T25FW, the MSWS-12, the 2-MWT, 
and the CGI correlated significantly with each other.
Following physicians’ overall judgement, 70.37% of 
subjects were characterized as RFs. Our clinical 
responder subgroup showed significant improvement 
in all four walking tests. The MSWS-12 questionnaire 
and the 2-MWT showed the greatest improvement, 
while walking speed alone had an overall improve-
ment below 20%, which has been described as a clini-
cally meaningful change.29 Our findings suggest that 
following criteria based on physicians’ global judge-
ment manifest clinical relevant response of fampri-
dine regarding other gait characteristics, as our 
subjects showed the greatest response in walking 
endurance and self-perceived disability. A similar 
proportion of RF was found by Allart et al.,16 who 
defined RFs as those with an improvement of 15% in 
the T25FW, 2-MWT, or the MSWS-12.
Subjective improvement defined by patients with the 
CGI, and significant response in the MSWS-12 crite-
ria proposed by Hobart,30 was lower than responder 
rate as defined by the neurologist (61.9% vs 50.79% 
vs 70.37%, respectively, see Figure 2), which sug-
gests that clinical judgement was not influenced by 
patient’s assessment of improvement only, and that it 
also includes information about walking endurance 
and gait speed.
The combination of the T25FW and the MSWS-12 
offered the best sensitivity and specificity for deter-
mining response to fampridine according to both 
neurologists’ and patients’ classification. Although 
Figure 2. Percentage of responders in our sample applying different responder criteria: Goodman: subjects showing an 
improvement of 20% or more in the T25FW; Hobart: subjects showing an improvement of 6.9 points or greater in the 
MSWS-12; Allart: subjects showing an improvement of 15% or greater in the T25FW, the 2-MWT, or the MSWS-12; 
Physicians’ judgement: subjects showing a clinical significant improvement in the T25FW, 2-MWT, MSWS-12, and FAP, 
according to physician’s judgement after 2 weeks of treatment. This criterion was applied in this study; Patients’ CGI: 
represents subjects who received a CGI score of 5 or greater; Cut-off: subjects showing an improvement greater than 21% 
(percentage improvement in T25FW + percentage improvement in MSWS-12), according to our ROC curve analysis.
2-MWT: 2-minute walk test; FAP: Functional Ambulation Profile; MSWS-12: 12-item Multiple Sclerosis Walking Scale; T25FW: timed 
25-foot walk test.
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patients receiving a positive CGI score had a similar 
performance to RF, and a great proportion of CGI 
responders were also RF (96.58%), AUC values were 
greater for RF according to physicians’ judgement as 
compared to response defined by the CGI. There was 
no significant difference in performance between RF 
and CGI responders due to the high overlap between 
those two rating-based subgroups. Similar to our find-
ings, Baert et al.3 reported that the MSWS-12 and 
long capacity tests are the most sensitive for evaluat-
ing gait improvement in MS patients receiving physi-
cal rehabilitation.
Neither level of disability nor diagnosis had an effect 
on the response to fampridine in any of the tests 
included in the multimodal walking model, or the 
CGI. A similar observation was made by Goodman 
et al.5–8 in previous trials, which suggests that all sub-
sets of MS patients with walking disability might 
profit from the use of fampridine.
As mentioned above, it has been suggested that 
the threshold for determining a clinical significant 
response to fampridine is a 20% speed improvement 
in the T25FW6,7 and a 6.9-point improvement in the 
MSWS-12.30,31 Applying different criteria to deter-
mine RFs in our sample would affect the proportion 
of RFs and NRFs, with the greatest proportion of RF 
being determined by physicians’ judgement (see 
Figure 2).
There is a gap between subjects showing any 
improvement, as defined by the EMA,11 and those 
with improvement ⩾20% in the T25FW. Allart et al., 
applying different response criteria, as described 
above, reported a similar response rate to our study. 
This suggests that in a real-world clinical setting, a 
larger number of subjects demonstrate positive effects 
from fampridine than previously suggested in con-
trolled clinical trials.
In our study, a control group was not included. 
Conceptually, without such a group, beneficial altera-
tions in walking behavior, as observed in this study, 
cannot be attributed to onset of fampridine treatment 
directly. Given the extensive body of literature in strong 
support of such an effect of fampridine,5–8,12,13,16,32–34 
and the methodological emphasis of the current work, 
this limitation might not be critical.
To reduce complexity in the analysis of spatiotempo-
ral gait patterns, we limited our analysis to the FAP 
score as a validated outcome for assessing gait in MS 
patients;22,35 an assessment of each gait parameter 
itself would be out of the scope of this paper.
This study provides new information on the useful-
ness of multimodal walking testing with fampridine 
treatment and suggests that current treatment response 
criteria for fampridine should be reevaluated for the 
clinical setting in subjects with MS and gait impair-
ment in order to match clinical study outcomes and 
the regulations of health authorities like the EMA.36 
We found evidence that physicians’ global judgement 
is a reliable outcome for determining response to fam-
pridine over time, and a combination of objective 
tests and patient-reported outcomes might become the 
most useful and efficient standardized test setting for 
such “real-world” problems.
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